MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10549-026-07912-w

Медицинская библиотека · Breast cancer research and treatment · 2026

Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.

Soyano Muller Aixa E, Goodridge Dawn N, Mo Qianxing, Whiting Junmin, Khakpour Nazanin, Lee Marie Catherine, Laronga Christine, Armaghani Avan J, Han Hyo, Soliman Hatem, Costa Ricardo, Loftus Loretta, Hoover Susan J, Kiluk John V, Jameel Zena, Czerniecki Brian J, Khong Hung T

СтатьяКлиническое исследование II фазыПеревод в очереди

Аннотация

PURPOSE: Hormone receptor-positive (HR+), HER2-negative breast cancer represents the most common subtype of breast cancer and is characterized by a risk of late recurrence. Neoadjuvant endocrine therapy with aromatase inhibitors (AIs) is a well-tolerated option in postmenopausal women; however, strategies to enhance its efficacy are needed. Combination of AI with immunotherapy is a promising approach. We evaluated the efficacy and safety of combining an AI with the anti-program death ligand 1 antibody durvalumab in the neoadjuvant setting.

METHODS

This single-arm, phase II study used a Simon two-stage design. Postmenopausal patients with early-stage HR+/HER2-negative breast cancer received durvalumab every 4 weeks plus daily AI for 6 months prior to surgery. The primary endpoint was the achievement of a modified Preoperative Endocrine Prognostic Index (mPEPI) score of 0.

RESULTS

Seventeen patients were enrolled and received durvalumab plus daily AI for six months before surgery. Treatment was well tolerated, with most adverse events being grade 1-2. A clinical complete response was seen in 58.8% of patients, although no pathologic complete responses occurred. Among the first 14 patients, one achieved mPEPI 0, which did not meet criteria to proceed to stage two. Overall, three patients (17.6%) achieved mPEPI 0.

CONCLUSION

Neoadjuvant durvalumab plus AI was safe but demonstrated limited pathologic efficacy in this unselected HR + HER2-negative population. Favorable long-term outcomes support further investigation of immunoendocrine combinations in HR + HER2-negative breast cancer in biomarker-selected subgroups.

TRIAL REGISTRATION: NCT03874325. Date of registration. 12-03-2019.

Для цитирования: Soyano Muller Aixa E, Goodridge Dawn N, Mo Qianxing, Whiting Junmin, Khakpour Nazanin, Lee Marie Catherine, Laronga Christine, Armaghani Avan J, Han Hyo, Soliman Hatem, Costa Ricardo, Loftus Loretta, Hoover Susan J, Kiluk John V, Jameel Zena, Czerniecki Brian J, Khong Hung T. Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.. Breast cancer research and treatment. 2026. DOI: 10.1007/s10549-026-07912-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.